

Dear NICE

Thank you for the opportunity to comment on the appraisal consultation document for the above single technology appraisal.

I have received comments from a colleague in the Department of Health, as follows:

**"My first comment concerns the simulated population used for the health economic modelling. The population has a mean age of 63 years. Whilst this is probably reflective of the population with diabetic maculopathy in general, I wonder whether there would be additional benefit in quality of life for younger individuals with the condition.**

**Secondly, is there any differential benefit for people with type 1 or type 2 diabetes, or are the studies too small to detect any discernable differences?**

**Thirdly, whilst no restriction is placed on the use of this agent in terms of HbA1c, I think it is important to point out that the HbA1c at the time of the decision to treat with this agent is of only modest value in determining whether an individual has good glycaemic control, as the development of retinopathy reflects glycaemic control over a very prolonged period".**